A Phase II, Randomized Trial of Standard of Care, With or Without Midostaruin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With FLT3-ITD Mutated Acute Myeloid Leukemia
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
To determine if the addition of midostaurin (PKC412) to Standard of Care (SOC) therapy reduces relapse in FLT3-ITD mutated AML patients receiving an allogenetic hematopoietic stem cell transplant,
Fields of Study & Subjects
Acute Myeloid Leukemia Research
Hematopoietic Stem Cell Transplantation
Retinoids in leukemia and cellular processes
Publication details
- Journal / source
- Vivli
- Publication date
- 27 March 2026
- Language
- EN
- Document type
- Dataset